title: Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.
abstract: Multiple myeloma (MM) is a malignant plasma cell disease. Several proinflammatory cytokines produced by malignant plasma cells and bone marrow (BM) stromal cells are involved in the pathogenesis of the disease. We evaluated serum levels of the proinflammatory cytokines Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Interleukin-8 (IL-8), macrophage inflammatory protein-1α (MIP-1α), in MM patients before treatment, and determined its significance in tumor progression. We also analyzed the correlation between measured parameters with proliferating cell nuclear antigen (PCNA). Forty-four MM patients and 20 healthy controls were studied. Serum levels of the proinflammatory cytokines were measured using enzyme-linked immunosorbent assay (ELISA), whereas PCNA value in the BM was determined by immunohistochemistry staining. The mean concentrations of the measured cytokines were significantly different among the three stages of disease, with higher values in advanced disease stage. Furthermore, patients with MM had significantly higher serum levels of the measured cytokines than in controls. A positive correlation was found between IL-6 with IL-1β, IL-8 and MIP-1α. Similarly, IL-8 and MIP-1α were positively correlated with markers of disease activity such as β2 microglobulin and LDH. The proliferation index, determined by PCNA immunostaining, was higher in advanced disease stage. Furthermore PCNA value correlated significantly with β2 microglobulin, LDH and the levels of the measured cytokines. Our results showed that the proliferative activity, as measured with PCNA, increases in parallel with disease stage. The positive correlation between PCNA and other measured mediators supports the involvement of these factors in the biology of myeloma cell growth and can be used as markers of disease activity and as possible therapeutic targets.
authors.affiliation: Department of Haematology, University Hospital of Heraklion, Crete, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Tsirakis
authors.forename: C A
authors.initials: CA
authors.lastname: Pappa
authors.forename: M
authors.initials: M
authors.lastname: Kaparou
authors.forename: V
authors.initials: V
authors.lastname: Katsomitrou
authors.forename: A
authors.initials: A
authors.lastname: Hatzivasili
authors.forename: T
authors.initials: T
authors.lastname: Alegakis
authors.forename: A
authors.initials: A
authors.lastname: Xekalou
authors.forename: E N
authors.initials: EN
authors.lastname: Stathopoulos
authors.forename: M G
authors.initials: MG
authors.lastname: Alexandrakis
mesh_terms: D000368:Aged; D049109:Cell Proliferation; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000473:pathology; D009367:Neoplasm Staging; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism*; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D016207:Cytokines; D008077:Lipoproteins, LDL; D018809:Proliferating Cell Nuclear Antigen; D001613:beta 2-Microglobulin
references.citation: J Leukoc Biol. 1996 Jan;59(1):61-6
references.pmid: 8558069
references.citation: Eur J Haematol. 2010 Aug;85(2):114-9
references.pmid: 20477863
references.citation: Int Rev Immunol. 1998;16(3-4):249-84
references.pmid: 9505191
references.citation: J Intern Med. 2011 Jan;269(1):16-28
references.pmid: 21158974
references.citation: Cell Prolif. 2010 Dec;43(6):579-83
references.pmid: 21039996
references.citation: J Leukoc Biol. 1995 May;57(5):752-62
references.pmid: 7539029
references.citation: J Interferon Cytokine Res. 2006 Feb;26(2):83-95
references.pmid: 16487028
references.citation: Exp Hematol. 2010 Oct;38(10):860-7
references.pmid: 20619313
references.citation: Cancer. 1975 Sep;36(3):842-54
references.pmid: 1182674
references.citation: J Intern Med. 2001 Aug;250(2):91-104
references.pmid: 11489059
references.citation: Blood. 1999 Jan 1;93(1):300-5
references.pmid: 9864174
references.citation: Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91
references.pmid: 11544106
references.citation: Leukemia. 2002 Mar;16(3):382-5
references.pmid: 11896542
references.citation: Leuk Res. 2007 May;31(5):591-8
references.pmid: 16879867
references.citation: Am J Hematol. 2000 Oct;65(2):132-5
references.pmid: 10996830
references.citation: Br J Cancer. 2003 Mar 24;88(6):855-62
references.pmid: 12644822
references.citation: Br J Haematol. 2005 Apr;129(2):248-56
references.pmid: 15813853
references.citation: J Immunol. 2003 Mar 15;170(6):3369-76
references.pmid: 12626597
references.citation: Blood. 1996 Mar 15;87(6):2095-147
references.pmid: 8630372
references.citation: Cancer. 2003 May 15;97(10):2440-52
references.pmid: 12733143
references.citation: J Pathol. 1992 Jan;166(1):45-52
references.pmid: 1347081
references.citation: Blood. 2000 Jul 15;96(2):671-5
references.pmid: 10887133
references.citation: Cytokine. 2007 Feb;37(2):171-5
references.pmid: 17446083
references.citation: Anticancer Res. 1994 May-Jun;14(3A):787-92
references.pmid: 7915507
references.citation: Int J Immunopathol Pharmacol. 2004 Jan-Apr;17(1):49-56
references.pmid: 15000866
references.citation: Br J Haematol. 2003 Jan;120(1):53-5
references.pmid: 12492576
references.citation: Ann Hematol. 2003 Jan;82(1):19-23
references.pmid: 12574959
references.citation: Trends Immunol. 2004 Apr;25(4):201-9
references.pmid: 15039047